BioSpace News Archive

ICON plc, a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020.

CMAB completed a full scope development and manufacturing project for Q-1802 in 9 months for dual IND filing in China and the US Completion of the project demonstrates the significant speed to clinic achievable with CMAB’s fully integrated development and manufacturing platform QureBio’s bispecific antibody Q-1802 will enter clinical trials to assess treatment of solid tumors s

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2020. “Over the course of the first quarter 2020, the value of our unique discovery a

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients wi

Smiths Medical, a leading global medical device manufacturer, announces today the acquisition of the business of Access Scientific, LLC, a privately-held company based in San Diego, CA.

XLerateHealth (XLH), its affiliate, the Southeast XLerator Network (XLN), and XLN Academic Lead, the University of Kentucky, are pleased to announce that the National Institutes of Health (NIH) has approved XLN’s External Advisory Committee’s (EAC) recommendation to fund the continued development of seven biomedical innovations that represent various areas of technology, from medical devices to diagnostics and therapeutics.

- Funding will also enable the addition of new trial sites to accelerate completion of the Phase 2 clinical trial - Data continues to demonstrate the safety and efficacy of onvansertib as a promising new treatment for patients with KRAS-mutated mCRC [13-May-2020] SAN DIEGO , May 13, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-sta

- Induced pluripotent stem cell (iPSC)-derived MSCs demonstrate higher-level secretion of anti-inflammatory proteins and greater expansion potential than conventional, donor-derived MSCs - Data include comparative therapeutic benefit in an experimental autoimmune encephalomyelitis (EAE) mouse model [13-May-2020] CRANFORD, N.J. , May 13, 2020 /PRNewswire/ --

Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its first quarter 2020 financial results and provide a corporate update on Thursday, May 14, 2020. Management will host a conference call on Thursday, May 14, 2020 at 6:00 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, there will

Hospitals and institutions are regularly using imaging as a frontline tool for triaging patients, and disinfection after use can be time consuming when every second counts. To meet the need for fast decontamination, Canon Medical Systems USA, Inc. has partnered with Surfacide to offer Helios – a rapid decontamination tool for its imaging equipment.